Skip to main content
Kaysia Ludford, MD, Internal Medicine, Boston, MA

Kaysia Ludford MD

Hematology/Oncology


Physician

Join to View Full Profile
  • 75 Francis StBoston, MA 02115

  • Phone+1 617-732-5500

Dr. Ludford is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Texas Health Science Center at Houston/M D Anderson Cancer Center
    University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2017 - 2020
  • Mass General Brigham/Brigham and Women's Hospital
    Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2014 - 2017
  • Yale School of Medicine
    Yale School of MedicineClass of 2014

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • GA State Medical License
    GA State Medical License 2022 - 2026
  • AL State Medical License
    AL State Medical License 2022 - 2025
  • AZ State Medical License
    AZ State Medical License 2022 - 2025
  • LA State Medical License
    LA State Medical License 2022 - 2025
  • MS State Medical License
    MS State Medical License 2022 - 2025
  • OK State Medical License
    OK State Medical License 2022 - 2025
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Hematology
    American Board of Internal Medicine Hematology
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology
  • Join now to see all

Publications & Presentations

PubMed

Lectures

  • Evaluation of complete pathological remission rates in surgically resected MSI-high metastatic colorectal cancers (mCRC). 
    2019 ASCO Annual Meeting - 6/1/2019
  • Phase II trial of nab-paclitaxel (ABI) and ipilimumab (ipi) in patients with treatment naïve metastatic melanoma. 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • MD Anderson Research Highlights Special Edition: ESMO 2024
    MD Anderson Research Highlights Special Edition: ESMO 2024September 10th, 2024
  • Immunotherapy and… Nothing Else? Studies Test Potential Paradigm Shift in Cancer Treatment
    Immunotherapy and… Nothing Else? Studies Test Potential Paradigm Shift in Cancer TreatmentFebruary 23rd, 2023

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: